RESCUE-II Study Published on Thrombolex Bashir Catheter for PE

June 25, 2025—Thrombolex, Inc., a developer of treatments for arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II study. The study assessed the company’s Bashir endovascular catheter (BEC) in treating pulmonary embolism (PE) on the table (OTT). The study was published by Vladimir Lakhter, DO, et al in JACC: Advances.

“The RESCUE-II study demonstrated encouraging safety and feasibility, while reinforcing the clinical value of this novel OTT protocol,” commented Dr. Lakhter in the company’s press release. “These results warrant further investigation in larger, multicenter trials like the RAPID-PE study, which is currently enrolling patients.”

According to the company, the single-center, prospective RESCUE-II study evaluated the safety and feasibility of OTT pharmacomechanical lysis without postprocedural infusion when treating patients with acute intermediate-risk PE. The study enrolled nine patients who were treated with low-dose recombinant tissue-type plasminogen activator (4 mg per pulmonary artery) using the BEC. At 48 hours, the mean right ventricular to left ventricular ratio decreased by 22.3%, and pulmonary artery obstruction, as measured by the Refined Modified Miller Index, was reduced by 29.2%. There were no major bleeding events, no deaths, or serious adverse events through 30-day follow-up, reported Thrombolex.

An independent data safety monitoring board adjudicated all clinical events for the RESCUE-II study, and imaging data were assessed by an independent core laboratory, advised the company.